H.C. Wainwright raised the firm’s price target on Corcept Therapeutics to $32 from $30 and keeps a Buy rating on the shares post the Q2 results. The analyst says the company’s growth momentum continues in Cushing’s syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics reports Q2 EPS 25c, consensus 15c
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- CORT Upcoming Earnings Report: What to Expect?
- Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Corcept announces publication of analysis of Phase 2 trial of relacorilant